More MS news articles for May 2000

Boston Life Sciences Achieves Milestone in Experimental Spinal Cord Injury

Nerve Fibers That Control Movement Stimulated to Re-Grow Right Through the Site of Injury

Updated 11:35 AM ET April 28, 2000
Current quotes (delayed 20 mins.) BLSI  7 1/4  -3/16  (-2.52%)

BOSTON (BW HealthWire) - Boston Life Sciences, Inc. (NASDAQ:BLSI) announced that Inosine, one of the Company's nerve growth factors, had stimulated "substantial" re-growth of severed spinal cord motor nerve fibers through the area of experimental injury. To the Company's knowledge, this represents the first time that such a feat has been accomplished experimentally. Last year the Company announced that Inosine stimulated substantial cross-over sprouting of motor axons in the injured cord, effectively by-passing the injury and re-innervating the spinal cord below. These results were published in the Proceedings of the National Academy of Sciences (vol. 96; pages 13486-13490; 1999). In the present study a hemi-transection of the corticospinal tract was made in rats and Inosine was administered to the motor cortex that gave rise to the transected fibers. After two weeks of treatment, the spinal cord was examined for microscopic evidence of re-growth through the injury. In four out of five treated rats, new fibers were seen coursing through the injury to re-establish their distal connections.

"To our knowledge, such regrowth through the injured corticospinal tract has not previously been documented in the scientific literature. We hope to submit these results for publication shortly," stated Dr. Marc Lanser, MD, Chief Scientific Officer of BLSI. "This represents a giant step forward in our spinal cord program, since these results indicate that motor function can potentially be re-established under the control of the same area of the brain that gave rise to the injured spinal cord fibers. Rehabilitation could theoretically take place without having to retrain different areas of the brain to take over the lost motor function. These results bring us that much closer to our goal of initiating human trials in spinal cord injury. We hope to duplicate these results in primates with the goal of demonstrating functional improvement prior to initiating human trials," added Dr. Lanser.

BLSI is developing Inosine and AF-1 for the regenerative treatment of spinal cord injuries and stroke.

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: Altropane, a radioimaging agent for the diagnosis of Parkinson's Disease and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; fusion toxins for the treatment of cancer and multiple sclerosis; novel therapies for the treatment of Parkinson's Disease and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K/A.

Contact: Investors Boston Life Sciences, Inc. Maria Zapf 617.425.0200 x.17 or The Trout Group Brandon Lewis 212.477.9007 x.15 or Corporate Boston Life Sciences, Inc. Marc Lanser, MD Chief Scientific Officer 617.425.0200 or Media Schwartz Communications
Jim Weinrebe 781.684.0770